CRISPR THERAPEUTICS AG
Profile
Company Names
CRISPR THERAPEUTICS AG
Addresses
BAARERSTRASSE 14, ZUG, V8 6300
BAARERSTRASSE 14, ZUG, V6 6300
AESCHENVORSTADT 36, BASEL, V8 4051
Phone Numbers
+41 (0)41 561 32 77
41-61-228-7800
Entity Type:
CORPORATION
Industry:
OTHER HEALTH CARE, BIOTECHNOLOGY
Year Incorporated:
2013
State Incorporated:
SWITZERLAND
Total Amount Raised:
$36,000,000.00
Number of Funding Rounds:
2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2020-03-11
$1,000,000.00
$1,000,000.00
$0.00
Equity
1
2016-10-20
$35,000,000.00
$35,000,000.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
MARC
BECKER
EXECUTIVE OFFICER
APOLLO CO-INVESTORS VIII (E), L.P.
| APOLLO CO-INVESTORS VIII (C), L.P.
| APOLLO CO-INVESTORS VIII (B), L.P.
| APOLLO OVERSEAS PARTNERS VIII, L.P.
| APOLLO OVERSEAS PARTNERS (I) VIII, L.P.
| APOLLO OVERSEAS PARTNERS (DELAWARE) VIII, L.P.
| APOLLO OVERSEAS PARTNERS (DELAWARE 892) VIII, L.P.
| APOLLO INVESTMENT FUND VIII, L.P.
| APOLLO INVESTMENT FUND (I) VIII, L.P.
| PINNACLE AGRICULTURE HOLDINGS, LLC
| PRIME SECURITY SERVICES TOPCO PARENT, L.P.
| APOLLO ANRP CO-INVESTORS II (B), L.P.
| APOLLO NATURAL RESOURCES PARTNERS II, L.P.
| CRISPR THERAPEUTICS AG
| APOLLO SPECIAL SITUATIONS FUND, L.P.
| APOLLO OVERSEAS PARTNERS (I) IX, L.P.
| APOLLO OVERSEAS PARTNERS (DELAWARE) IX, L.P.
| APOLLO OVERSEAS PARTNERS (DELAWARE 892) IX, L.P.
| APOLLO INVESTMENT FUND IX, L.P.
| APOLLO INVESTMENT FUND (I) IX, L.P.
| APOLLO OVERSEAS PARTNERS IX, L.P.
| APOLLO OVERSEAS PARTNERS (LUX) IX SCSP
| SCA ACQUISITION HOLDINGS, LLC
| APOLLO U.S. REAL ESTATE PARTNERS III (TE), L.P.
| APOLLO U.S. REAL ESTATE PARTNERS III (OFFSHORE), L.P.
| APOLLO U.S. REAL ESTATE FUND III, L.P.
ALI
BEHBAHANI
DIRECTOR
ROTATION MEDICAL INC
| DENALI MEDICAL II, INC.
| MINERVA SURGICAL INC
| PROSPEX MEDICAL III, INC.
| OCULEVE, INC.
| CVRX INC
| IVANTIS, INC.
| ADAPTIMMUNE LTD
| CARDIONOMIC, INC.
| CVRX, INC.
| SOLACE THERAPEUTICS INC
| CRISPR THERAPEUTICS AG
| OYSTER POINT PHARMA, INC.
| GENOCEA BIOSCIENCES, INC.
| BLACK DIAMOND THERAPEUTICS, INC.
| SPYGLASS OPHTHALMICS, INC.
| ARCELLX, INC.
| NKARTA, INC.
| NEA BH SPV, L.P.
| NEA BH SPV II, L.P.
| MONTE ROSA THERAPEUTICS, INC.
| 858 THERAPEUTICS, INC.
| NEW ENTERPRISE ASSOCIATES 18, L.P.
| NEA 18 VENTURE GROWTH EQUITY, L.P.
| FIRSTLIGHT BIO, INC.
| NEXO THERAPEUTICS, INC.
| LAUNCHPAD THERAPEUTICS, INC.
| NEA SH SPV, L.P.
| SPYGLASSPHARMA, INC.
| NEA RP SPV, L.P.
| NEA CH SPV, L.P.
| NEA TS 2024 SPV, L.P.
| NEA SECONDARY OPPORTUNITY FUND, L.P.
| TUNE THERAPEUTICS, INC.
BRADLEY
BOLZON
DIRECTOR
METABOLEX, INC.
| FLEXION THERAPEUTICS INC
| INCEPTION 3, INC.
| INCEPTION 4, INC.
| VERSANT VENTURE CAPITAL V, L.P.
| VERSANT AFFILIATES FUND V, L.P.
| VERSANT OPHTHALMIC AFFILIATES I, L.P.
| VERSANT VENTURE CAPITAL V (CANADA), LP
| INCEPTION 5, INC.
| INCEPTION IBD, INC.
| CRISPR THERAPEUTICS AG
| VERSANT VENTURE V AIV FEEDER HOLDINGS, L.P.
| VERSANT VENTURE V AIV, L.P.
| VERSANT VENTURE CAPITAL VI, L.P.
| MISTRAL THERAPEUTICS, INC.
| VERSANT VOYAGEURS I FEEDER, L.P.
| BLACK DIAMOND THERAPEUTICS, INC.
| VERSANT VENTURE CAPITAL VII, L.P.
| NORTHERN MOSAIC LP
| VERSANT VOYAGEURS I, L.P.
| VERSANT VOYAGEURS I PARALLEL, L.P.
| MONTE ROSA THERAPEUTICS, INC.
| VERSANT VANTAGE II, L.P.
| VERSANT VOYAGEURS II, L.P.
| VERSANT VOYAGEURS II (CANADA), L.P.
| VERSANT VENTURE CAPITAL VIII, L.P.
| VERSANT VENTURE CAPITAL VIII (CANADA), L.P.
| VERSANT VOYAGEURS III, L.P.
| VERSANT VOYAGEURS III (CANADA), L.P.
| VERSANT VANTAGE III, L.P.
| VERSANT VANTAGE III (CANADA), L.P.
| VERSANT VENTURE CAPITAL IX, L.P.
| VERSANT VENTURE CAPITAL IX (CANADA), L.P.
| VERSANT VENTURE CAPITAL SPV I (SAB), L.P.
SIMEON
GEORGE
DIRECTOR
SEMPRUS BIOSCIENCES CORP
| GENOCEA BIOSCIENCES, INC.
| HTG MOLECULAR DIAGNOSTICS INC
| AUXOGYN INC
| EFFECTOR THERAPEUTICS, INC.
| HTG MOLECULAR DIAGNOSTICS, INC
| AUXOGYN, INC.
| PRINCIPIA BIOPHARMA INC.
| PROGYNY, INC.
| TP THERAPEUTICS, INC.
| CRISPR THERAPEUTICS AG
| SR ONE CO-INVEST I, LLC
| SIMCHA THERAPEUTICS HOLDING COMPANY, LLC
| ADARX PHARMACEUTICALS, INC.
| SR ONE CAPITAL FUND II-B, LP
| SR ONE CAPITAL FUND II-A, LP
| AVENZO THERAPEUTICS, INC.
| REZO THERAPEUTICS, INC.
| SR ONE CAPITAL FUND III, LP
SIMEON
J.
GEORGE
DIRECTOR
JOHN
GREENE
DIRECTOR
SAMARTH
KULKARNI
EXECUTIVE OFFICER, DIRECTOR
KURT
VON EMSTER
DIRECTOR
METABOLEX, INC.
| SOMAXON PHARMACEUTICALS, INC.
| VENBIO SELECT FUND LTD.
| VENBIO SELECT FUND LLC
| VENBIO GLOBAL STRATEGIC FUND, L.P.
| CYMABAY THERAPEUTICS, INC.
| SUTROVAX, INC.
| CRISPR THERAPEUTICS AG
| ABINGWORTH BIOVENTURES VII LP
| ATTENUA, INC.
| ORBUS THERAPEUTICS, INC.
| VERA THERAPEUTICS, INC.
| IAMBIC THERAPEUTICS, INC.
THOMAS
WOIWODE
DIRECTOR
EURO VENTURES 4, INC.
| AUDENTES THERAPEUTICS, INC.
| KANYOS BIO, INC.
| INCEPTION IBD, INC.
| CRISPR THERAPEUTICS AG
| VERSANT VENTURE V AIV FEEDER HOLDINGS, L.P.
| VERSANT VENTURE V AIV, L.P.
| VERSANT VENTURE CAPITAL VI, L.P.
| TEMPEST THERAPEUTICS, INC.
| VERSANT VOYAGEURS I FEEDER, L.P.
| VERSANT VENTURE CAPITAL VII, L.P.
| VIVIDION THERAPEUTICS, INC.
| VERSANT VOYAGEURS I, L.P.
| VERSANT VOYAGEURS I PARALLEL, L.P.
| LYCIA THERAPEUTICS, INC.
| JENGU THERAPEUTICS, INC.
| VERSANT VANTAGE II, L.P.
| VERSANT VOYAGEURS II, L.P.
| VERSANT VOYAGEURS II (CANADA), L.P.
| VERSANT VENTURE CAPITAL VIII, L.P.
| VERSANT VENTURE CAPITAL VIII (CANADA), L.P.
| SANTA ANA BIO, INC.
| TEMPEST THERAPEUTICS, INC.
| VERSANT VOYAGEURS III, L.P.
| VERSANT VOYAGEURS III (CANADA), L.P.
| VERSANT VANTAGE III, L.P.
| VERSANT VANTAGE III (CANADA), L.P.
| VERSANT VENTURE CAPITAL IX, L.P.
| VERSANT VENTURE CAPITAL IX (CANADA), L.P.
| VERSANT VENTURE CAPITAL SPV I (SAB), L.P.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D/A
OTHER HEALTH CARE
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2020-03-11
D
OTHER HEALTH CARE
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2020-03-11
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2016-10-20
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
